CapsoVision, Inc. (CV)
NASDAQHealth CareMedical - DevicesSnapshot 2026-11-05
$6.20-9.49%
Close 2026-11-05 · 1-day change
NASDAQHealth CareMedical - DevicesSnapshot 2026-11-05
QuarterlyIQ Insights · CV
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance sits below its industry cohort — worth keeping an eye on, though it has not freshly broken.
One-year growth currently built into the price, compared with our model's estimate.
| Measure | Marker shape | Value |
|---|---|---|
| Growth built into the price | circle | 377.8% |
| Our one-year growth estimate | diamond | 32.9% |
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
No outside relationship met the current evidence threshold.
Based on historical daily prices through 2026-11-05.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Growth built into the price is above our model estimate.
The price assumes 344.9 percentage points more one-year growth.
The one-year revenue growth assumption on Valuation.
Worth watching into the next print: this name is on a run of consecutive earnings misses and is a smaller-cap name (higher miss base rate). A fundamental tilt, not a price call.
Model as of 2026-11-05 · Compared with 43 industry peers
CV — debt issuance
Dated 2026-09-18
Entry into a Material Definitive Agreement. On September 17, 2026, CapsoVision, Inc. (the “Company”) entered into a securities purchase agreement (the “Purchase Agreement”) with certain investors (the “Purchasers”), which provides for the issuance and sale, in a registered direct offering by the Company, of an aggregate of 3,163,444 shares (the “Shares”) of its common stock, par value $0.001 per share (the “Common Stock”), at a purchase price of $5.69 per share of Common Stock (the “Offering”…
Why it matters: Q2 revenue rose 10%, while capsule sales rose 13%. Continued growth would support the case for wider use of CapsoCam Plus.
Supportive ifQ3 revenue grows at least 10% year over year, with capsule sales volume above the prior-year quarter.
Worry ifQ3 revenue is flat or down year over year, or capsule sales volume falls from the prior-year quarter.
Why it matters: A filing would mark a clear step toward bringing the colon capsule to market. A delay would weaken the stated timeline.
Supportive ifThe company confirms it sent the CapsoCam Colon 510(k) to the FDA by December 31, 2026.
Worry ifThe company says the submission slipped past Q4 2026 or reports a pause in the program.
Why it matters: Gross margin fell from 55% to 51% in Q2. More pressure from prices or tariffs could leave less money to cover costs.
Worry ifQ3 gross margin falls below 51%, the Q2 level, as price pressure or customs and tariff costs persist.
Less concerning ifQ3 gross margin is at least 51% and the company reports lower price or tariff pressure.
Why it matters: The company sold 3.16 million shares in September and has a $100 million ATM program. New share sales could add cash but also raise the share count.
Watch forNew filings show little or no ATM share sales, while cash remains at or above the June 30 level of $9.1 million.
Also watch forNew filings show further ATM share sales and cash below $9.1 million, or a sharp rise in shares outstanding.
We watch for confirming and disproving signals on each item. Resolutions are found automatically where possible and checked by hand for unclear cases. Last 90 days shown.
A larger daily loss that occurred about once in every 20 trading days.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$205 on $10,000 · ±2.1% | How much price usually moves either way. |
| Bad day | $1,000 loss on $10,000 · 10.0% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $6,782 loss on $10,000 · 67.8% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.
Why it matters: The FDA cleared AI Highlights on September 25. A U.S. launch would show the company is turning that clearance into a product doctors can use.
Supportive ifCapsoVision announces a U.S. commercial launch of AI Highlights, with the tool available to U.S. customers.
Worry ifThe company reports that the U.S. launch is delayed, or gives no launch update by its next earnings call.